Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach

Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach

Bhavesh Lakhotia,1 Ronan Mahon,1 Florian S Gutzwiller,2 Andriy Danyliv,1 Ivan Nikolaev,2 Praveen Thokala3 1Novartis Ireland Limited, Dublin, Ireland; 2Novartis Pharma, Basel, AG, Switzerland; 3PT Health Economics Ltd, Sheffield, UKCorrespondence: Ronan MahonTeam Head, Patient Access Services Product...

Full description

Bibliographic Details
Main Authors: Lakhotia B, Mahon R, Gutzwiller FS, Danyliv A, Nikolaev I, Thokala P
Format: Article
Language:English
Published: Dove Medical Press 2020-04-01
Series:International Journal of COPD
Subjects:
chronic obstructive pulmonary disease
indacaterol/glycopyrronium
cost-effective
exacerbation
markov model
Online Access:https://www.dovepress.com/modelling-the-cost-effectiveness-of-indacaterolglycopyrronium-versus-s-peer-reviewed-article-COPD

Internet

https://www.dovepress.com/modelling-the-cost-effectiveness-of-indacaterolglycopyrronium-versus-s-peer-reviewed-article-COPD

Similar Items